Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Welcome and Introduction to Vi3C

Sep

Today In Oncology

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Welcome and Introduction to Vi3C

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test

New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer

CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing

Robert Kyle Myeloma Expert Dies at 98